Lantheus (LNTH) Expected to Announce Earnings on Thursday

Key Points

• Lantheus is expected to report Q3 2026 earnings before Thursday’s market open, November 5. Analysts project earnings of $1.26 per share on revenue of $360.82 million; the earnings call is scheduled for 8:00 a.m. ET.
• In its previous quarter, Lantheus exceeded expectations with EPS of $1.55 versus the $1.30 consensus and revenue of $388.18 million. Quarterly revenue increased 2.7% year over year.
• Analyst sentiment is mostly cautious: three analysts rate the stock Buy and eleven rate it Hold, producing an overall Hold rating and an average price target of $107.44. Shares recently traded at $100.10, with a market capitalization of approximately $6.54 billion.

Lantheus (NASDAQ:LNTH - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $1.26 per share and revenue of $360.82 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. Lantheus's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.57 EPS. On average, analysts expect Lantheus to post $4.54 EPS for the current fiscal year and $5.61 EPS for the next fiscal year.

Lantheus Price Performance

LNTH stock opened at $100.10 on Thursday. The stock has a 50-day moving average price of $100.26 and a two-hundred day moving average price of $90.84. Lantheus has a 1 year low of $50.15 and a 1 year high of $111.86. The stock has a market cap of $6.54 billion, a PE ratio of 24.18 and a beta of -0.06. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. CJS Securities cut Lantheus from a "market outperform" rating to a "market perform" rating in a report on Tuesday, August 4th. Truist Financial downgraded Lantheus from a "buy" rating to a "hold" rating and reduced their price target for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. TD Cowen cut shares of Lantheus from a "buy" rating to a "hold" rating and dropped their target price for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Brookline Capital Markets downgraded Lantheus from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, William Blair set a $102.50 target price on shares of Lantheus in a research note on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $107.44.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company's products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.